Arginine
| Arg | |
|---|---|
| Salts [] | |
|---|---|
| Arginine didihydrate | |
| Arginine nitrate | |
| Arginine acetate | |
| Triarginine citrate | |
| Arginine hydrochloride | |
| Arginine aspartate | |
| Arginine malate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 174.20 g/mol [1] |
| Appearance | Prisms containing 2 mol H2O from water; anhydrous monoclinic plates from 66% alcohol [1] |
| Melting point | 244 dec °C [1] |
| Solubility | 182000 mg/L (at 25 °C) [1] |
| Predicted LogP | -4.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C6H14N4O2 |
| IUPAC name | (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid |
| SMILES | C(C[C@@H](C(=O)O)N)CN=C(N)N |
| InChI | InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1 |
| InChIKey | ODKSFYDXXFIFQN-BYPYZUCNSA-N |
| CAS number | 74-79-3 |
| UNII | 94ZLA3W45F |
| PubChem CID | 6322 |
Arginine (also known as L-(+)-Arginine, (S)-2-Amino-5-guanidinopentanoic acid, L-Arg, Arginina, Arginine, l-, Argininum, L-α-Amino-Δ-guanidinovaleric acid, 2-amino-5-guanidinovaleric acid, (2S)-2-amino-5-carbamimidamidopentanoic acid or (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid) is a substance of the amino acid class.
Chemistry
Salts []
Stereochemistry []
Arginine is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Arginine matches Lipinski's rule of five.Pharmacology
Mechanism of action []
Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production. [1]
Medical side effects []
30 side effects listed on drug labels in SIDER 4.1 (arginine).
- Anaphylactic shock
- Extravasation
- Haematuria
- Hypersensitivity
- Skin necrosis
- Skin exfoliation
- Surgery
- Sickle cell anaemia
- Decreased appetite
- Brain oedema
- Choking
- Dermatitis
- Rash
- Flushing
- Headache
- Lethargy
- Nasal obstruction
- Nausea
- Necrosis
- Hypoaesthesia
- Sensory loss
- Hyperhidrosis
- Swelling
- Tachycardia
- Vomiting
- Injection site reaction
- Rash macular
- Platelet count decreased
- Phlebitis superficial
- Paraesthesia oral
Indications
- Acrocyanosis
- Acromegaly
- Adenoma benign
- Craniopharyngioma
- Gigantism
- Insulin hypoglycemia
- Panhypopituitarism
- Pituitary dwarfism
- Trauma
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 6322, Arginine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/6322
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Arginine. UNII: 94ZLA3W45F. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/94ZLA3W45F
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 07:05:58 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 07:05:54 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 07:05:54 |
| gsrs | ok | 2026-11-20 07:06:02 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0000517) | 2026-11-20 07:05:54 |
| kegg | ok | 2026-11-20 07:05:56 |
| pubchem | ok | 2026-11-20 07:05:54 |
| missing (no r/tripreports posts mention it) | 2026-11-20 07:05:54 | |
| sider | ok | 2026-11-20 07:05:54 |
| structure | ok | 2026-11-20 07:05:54 |
| wikipedia | missing (no Wikipedia article with a drug infobox) | 2026-11-20 07:05:54 |